USAN drug names under consideration

USAN Council's statement on the use of USAN as domain names is that a name published by the United States Adopted Names (USAN) Program in the USP Dictionary of USAN and International Nonproprietary Names, and on the United States Adopted Names website shall be the effective equivalent of an intellectual property right for the relevant entities.

Visit United States Adopted Names FAQ to learn more.

Comments or protests should be addressed to Stephanie Shubat, USAN program director, American Medical Association, 330 North Wabash Ave., Suite 39300, Chicago, Illinois 60611, or via email: [email protected]. 

In order to ensure your "under consideration" USAN domain name is available, you should consider purchasing the .com, .net and .org domain names of the USAN under consideration. The optimal time to do this is when you receive the letter from the USAN Program informing you of the USAN Council's naming decision.

The following names for the drugs described are "under consideration" by the USAN Council:

Aderamastat: Treatment of COVID-19, allergic asthma and chronic obstructive pulmonary disease (COPD) and inflammatory airway diseases

Apinocaltamide: Treatment of epileptic encephalopathy and epilepsy

Berahyaluronidase Alfa: Treatment of diseases that can be targeted by protein-based therapies

Dazostinag: Treatment of advanced or metastatic solid tumors

Dazostinag Sodium: Treatment of advanced or metastatic solid tumors

Doruxapapogene Ralaplasmid: Treatment of respiratory papillomatosis (RPV)

Enlicitide Decanoate: Treatment of hypercholesterolemia and atherosclerotic cardiovascular disease

Ersodetug: Treatment of hypoglycemia

Ingitamig: Treatment of relapsed or refractory multiple myeloma

Lalikinogene Sifuplasmid: Treatment of respiratory papillomatosis (RPV)   

Lutetium Lu 177 Zadavotide Guraxetan: Treatment of prostate cancer

Nelistotug: Treatment of solid tumors

Oberotatug: Antineoplastic

Oberotatug Ravtansine: Antineoplastic

Puxitatug: Antineoplastic

Puxitatug Samrotecan: Antineoplastic

Samrotecan: Antineoplastic

Tizaterkib: Antineoplastic  

Tizaterkib Adipate: Antineoplastic  

Upacicalcet: Treatment of secondary hyperparathyroidism in adults with ESKD on hemodialysis

Upacicalcet Sodium: Treatment of secondary hyperparathyroidism in adults with ESKD on hemodialysis

Zaltenibart:Treatment of paroxysmal nocturnal hemoglobinuria (PNH)

Actinium Ac 225 Dotatate: Antineoplastic, radiolabeled agent

Azetukalner: For the treatment of partial-onset seizures (POS), primary generalized tonic-clonic seizures (PGTCS) and major depressive disorder (MDD)

Brigimadlin: Antineoplastic

Elritercept: Treatment of myelodysplastic syndromes and myelofibrosis

Flurimedrimer F18: Imaging agent for patients with neurodegenerative disorders

Migoprotafib: Antibacterial

Obicetrapib: Treatment of dyslipidemia

Obicetrapib Calcium: Treatment of dyslipidemia

Pivmecillinam: Antibiotic

Pivmecillinam Hydrochloride: Antibiotic

Rebisufligene Etisparvovec: Treatment of mucopolysaccharidosis (MPS) IIIA (Sanfilippo syndrome type A)

Riliprubart: Treatment of immune complement diseases

Sevasemten: Treatment of dystrophinopathy, including Duchenne muscular dystrophy and Becker muscular dystrophy

Sonavibart: Prevention of illness caused by influenza A infection

Survodutide: Treatment of obesity and NASH (non-alcoholic steatohepatitis)

Tamuzimod: Treatment of Inflammatory bowel disease (IBD)

Teprosulvose: Treatment of nasal adenocarcinoma in dogs

Teprosulvose Calcium: Treatment of nasal adenocarcinoma in dogs

Uzatresgene Autoleucel: Antineoplastic

Zandatrigine: Treatment of motor seizures

Zidesamtinib: Treatment of cancer

Zimistobart: Antineoplastic, checkpoint inhibitor

Anitocabtagene autoleucel: Antineoplastic; Treatment of multiple myeloma

Berberine ursodeoxycholate: Treatment of non-alcoholic fatty liver disease / non-alcoholic steatohepatitis (NAFLD/NASH), primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC)

Beroterkib: Antineoplastic

Eloralintide: Weight loss and glycemic control

Enekinragene inzadenovec: Treatment of osteoarthritis

Enmetazobactam: Antibacterial

Gridegalutamide: Treatment of prostate cancer

Ismidenon: Treatment of neurodegenerative diseases

Istisociclib: Antineoplastic

Labafenogene marselecobac: Treatment of phenylketonuria (PKU)

Mififilcon A: Contact lens material

Navacaprant: Treatment of major depressive disorder

Navacaprant sodium: Treatment of major depressive disorder

Osivelotor: Treatment of sickle cell disease

Pasifolate exatecan: Treatment of tumors that express folic acid receptors

Pirenzepine: Treatment of gastric ulcers and diabetic neuropathy

Progerinin: Treatment of Hutchinson-Gilford Progeria Syndrome (HGPS) and Werner Syndrome (WS)

Psilocybin: Treatment of treatment-resistant depression

Rivunatpagene miziparvovec: Treatment of Wilson disease

Sabirnetug: Treatment of Alzheimer’s disease

Selonabant: Treatment of acute cannabinoid intoxication

Sonrotoclax: Antineoplastic

Tuvimecirnon: Antineoplastic

Tuvimecirnon besylate: Antineoplastic

Tuvusertib: Antineoplastic

Vidutolimod: Antineoplastic

Zongertinib: Antineoplastic

Atirmociclib: Antineoplastic

Etalanetug: Treatment of Alzheimer’s disease

Frespaciguat: Treatment of pulmonary hypertension

Imneskibart: Antineoplastic

Imzokitug: Antineoplastic

Lunlekitug: Treatment of cardiovascular and inflammatory diseases

Mevrometostat: Antineoplastic 

Midafilcon b: Contact lens material

Naxtarubicin: Antineoplastic

Neldaleucel: Treatment of various hematologic malignancies [such as non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL)] and solid tumors

Nelitolimod: Antineoplastic

Nilotinib laurylsulfate: Treatment of myeloid leukemia

Ocadusertib: Treatment of autoimmune and inflammatory diseases, such as, psoriasis, rheumatoid arthritis (RA) or inflammatory bowel diseases (IBD)

Olomorasib: Antineoplastic

Pebezertinib: Antineoplastic

Ribitol: Treatment of limb-girdle muscular dystrophy type 2I/R9, FKRP-related (LGMD2I/R9)

Rilogrotug: Treatment of cachexia in cancer patients with elevated GDF-15 levels

Ruxoprubart: Treatment of complement mediated diseases

Salanersen: Treatment of spinal muscular atrophy (SMA)

Suzetrigine: Treatment of acute and neuropathic pain

Zelebrudomide: Antineoplastic